Research Article

Exosomes Derived from SW480-Resistant Colon Cancer Cells Are Promote Angiogenesis via BMP-2/Smad5 Signaling Pathway

Song Yang, Lei Yao, Xiaolong Wang, Hao Sun, Chaogang Du, Chengpeng Song, Jingyu Fu, Yongjun Wu, Hongwu Huang, Chuansi Wang, Yongsen Wang, and Yixiang Xie

Department of General Surgery, Lu’an Hospital of Anhui Medical University, Lu’an Hospital of Anhui Province, Anhui 237005, China

Correspondence should be addressed to Yixiang Xie; xieyx888@163.com

Received 2 March 2022; Revised 7 April 2022; Accepted 20 April 2022; Published 19 May 2022

Background. Multidrug resistance is the main cause of tumor recurrence and metastasis. Therefore, it is urgent to explore the mechanism and treatment of drug resistance of tumor cells. We aim to investigate the relationship between drug resistance and angiogenesis in SW480 colon cancer cells and the possible underlying mechanism.

Methods. Exosomes were extracted from SW480-sensitive or SW480-resistant colon cancer cells (SW480/oxaliplatin). The CCK-8 assay, migration assay, tube formation assay, qPCR, and Western blotting were performed in human umbilical vein endothelial cells (HUVECs). The underlying mechanisms were detected by Western blotting assays and BMP-2 si-RNA silencing assay in vitro and in vivo.

Results. The conditioned medium and exosomes of SW480/oxaliplatin cells promoted proliferation, migration, and tube formation of HUVECs. The expression of BMP-2 released by SW480/oxaliplatin exosomes was 2.3-folds higher than that by SW480 exosomes. Additionally, exosomal BMP-2 inhibiting the Smad signaling pathway induced the expression of vascular endothelial growth factor and CD31. Silencing of BMP-2 partly blocks the promoting effect of SW480/oxaliplatin exosomes on angiogenesis. Moreover, SW480/oxaliplatin cells increased the BMP-2 expression, consequently promoting angiogenesis in vivo.

Conclusions. SW480-resistant colon cancer exosomes promoted angiogenesis via the BMP-2/Smad signaling pathway, which is potential for the novel treatment for antiangiogenic therapies in colon cancer.

1. Introduction

Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies, with the third highest incidence and the second highest mortality in all malignant tumors [1, 2]. Chemotherapy is the primary treatment for advanced metastatic tumors [3]. However, multidrug resistance (MDR) often leads to poor efficacy of chemotherapy [3, 4]. The proliferation of drug-resistant cells is accelerated and metastases to distant regions, promoting increased angiogenesis [5]. Clinically, it is often found that tumor cells have multidrug resistance to a variety of chemotherapy drugs, resulting in tumor recurrence and tumor metastasis [6, 7]. Therefore, it is of great significance to explore the mechanism and treatment of tumor-resistant cells.

Exosomes are nanoscale vesicles with a diameter of 30-100 nm secreted by a variety of living cells, which can be stable in body fluids and play the role of information transmission between cells [8]. Exosomes contain a large number of maternal-cell-derived substances, including proteins, nucleic acids, and lipids, which participate in the regulation of tumor microenvironment in the way of transmitting material information [8]. It is involved in tumor growth, invasion and metastasis, immune escape, chemotherapy resistance, and radiotherapy tolerance [9, 10]. Studies on pancreatic ductal adenocarcinoma, breast cancer, ovarian cancer, liver cancer, and lung cancer have all shown that exosome transport is involved in chemotherapy resistance [11–13]. Exosomes secreted by tumor cells and stromal cells enhance and induced drug resistance in recipient cells by transferring their contents (DNA, mRNA, miRNA, Lnc RNA, protein, etc.) into recipient cells to alter their phenotype. However, few studies have focused on the effect of exosomes on tumor angiogenesis, especially in colon cancer.
2.2. Exosomes Isolation. The CM was prepared for the exosome isolation. All of the following centrifugations occurred at 4°C and cultured in an incubator at 37°C with 5% CO₂. All cells were inoculated in T25 flasks with 5% fetal bovine serum (FBS) medium for 48 h. Human umbilical vein endothelial cells (HUVECs) were purchased from the cell bank of Chinese Academy of Sciences (Shanghai, China) and were cultured in RPMI 1640 medium (Gibco) containing 10% fetal bovine serum. All cells were inoculated in T25 flasks and cultured in an incubator at 37°C with 5% CO₂. The subculture was performed once every 2 to 3 days.

Bone morphogenetic protein 2 (BMP-2) is a highly conserved, live opalsic, contained in the family of transgenic growth factor β (TGF-β) [14]. The main biological function of BMP-2 is to regulate cell proliferation, chemotaxis, and apoptosis, which is closely related to the growth and development of embryos, aging, and canceration [14]. Studies have shown that BMP2 is involved in the process of apoptosis, migration, and invasion of CRC, liver cancer, gastric cancer, and lung cancer [15–17] and affects the release of immune factors by tumor cells. Feng et al. found that BMP2 was highly expressed in liver cancer tissues [18]. Overexpression of BMP2 promoted cell proliferation, migration, invasion, microvascular density, and angiogenesis and reduced cell apoptosis [18]. However, the role of BMP-2 in drug resistance and angiogenesis is not fully understood.

In this study, we investigated the relationship between drug resistance and angiogenesis in human colon cancer SW480 cells. In addition, we also determined the role of SW480 cancer cell exosomes in angiogenesis and its potential mechanism.

2.3. Animal Experiments. The tumor was established in BALB/c nude mice. Six-week-old male BALB/c nude mice were randomly divided into three groups (n = 6): control, SW480-exos, and SW480/oxaliplatin-exos. The mice in the control group were injected subcutaneously with SW480 cells in the groin. The mice in the SW480 group were injected subcutaneously with SW480 cells+SW480-exos in the groin. The mice in the SW480/oxaliplatin-exos group were injected with SW480 cells+ SW480/oxaliplatin-exos. After inoculation for 28 days, mice were sacrificed and acquired the tumors tissues.

2.4. Cell Viability Assay. The cells were collected by centrifugation and made into cell suspension at a concentration of 5-10 x 10⁶/mL. 100 μL cell suspension was seeded into 96-well plates. The inoculated cell culture plates were placed in the incubator for 2 h. The culture supernatant was removed from the 96-well plate, and 100 μL of medium containing different concentrations of drugs was added. After incubation for 12, 24, and 48 h, 10 μL CCK8 solution (5 mg/mL) was added to each well and continued for 4 h. The 96-well plate was gently inverted to remove the supernatant. 150 μL dimethyl sulfoxide was added to each well and shaken at low speed for 10 min to make the crystals fully dissolved. Finally, the value of optical density was measured at 490 nm.

2.5. 5-Ethynyl-2′-Deoxyuridine (EdU) Assay. EdU assay kit (RiboBio, China) was used for the measurement of cell proliferation. Cells were cultured into 96-well plates with a density of 5 x 10³ for 24 h. After the treatment of SW480-exos or SW480/oxaliplatin-exos, cells were added with EdU (50 μmol/L) for 2 h. Then, cells were washed with PBS for 2 times for 5 min. 50 μL 4% paraformaldehyde was added into per well for 30 min incubation at room temperature. 50 μL glycine (2 mg/mL) was added and incubated in shaking table for 5 minutes. After washing with PBS again, cells were permeabilized with 0.5% TritonX-100 for 10 min. Then, cells were stained with existing Apollo dyeing reaction solution for 30 min in dark. After washing with PBS again, cells were then stained with existing Hoechst33342 for 30 min in dark to visualize the nuclei. Respective images were captured using confocal microscopy (Leica TCS SP8, Wetzlar, Germany).

2.6. Cell Migration Assay. Transwell Boyden chamber was used for cell migration assay. The gel was reconstructed by adding 200 microf DMEM medium to each well. Medium containing 10% FBS was added in Transwell lower chamber (600 μL/well). Cells suspension (5 x 10⁴) was prepared in a serum-free medium and then added into Transwell upper chamber and cultured for 24 h. After discarding the upper chamber fluid, cells were fixed with 10% neutral formaldehyde for 10 min and then stained with Giemsa for 10 min. After three times of PBS washing, three fields were randomly selected under an inverted microscope to count the number of cells.

2.7. Tube Formation Assay. HUVECs were planted in a six-well plate and grew to 100% fusion density (1 x 10⁶).
Figure 1: Continued.
Matrigel solution was diluted to 0.05% in the medium (0.5 mg/mL). The cells were grown in medium with 0.05% Matrigel for 24 h. A similar tubular structure was observed under a microscope (×10).

2.8. Immunoﬂuorescence. The prepared cell slides were soaked and washed with PBS for 3 times (5 min per time). The slides were ﬁxed with 4% paraformaldehyde for 15 min and then soaked with PBS for 3 times. Then, cells were permeated by 0.5% Triton X-100 at room temperature for 20 min. After washing with PBS, cells were blocked with 5% goat serum for 30 min at room temperature. After washing off the blocking ﬂuid, cells were incubated overnight with the primary antibody CD31 (Cat No.3528, Cell Signaling Technology) at 4°C. The slides were soaked and washed with PBS for 3 times and incubated with ﬂuorescent secondary antibody (Cat No. FITC-60299, Proteintech, Rosemont, IL, USA) at 20-37°C for 1 h. After the nucleus is stained with DAPI (Cat No. D9542, Sigma-Aldrich, St. Louis MO, USA), images were captured using confocal microscopy (Leica).

2.9. RNA Extraction and Quantitative Reverse Transcriptase-PCR (qRT-PCR). Total RNAs were extracted from cells with TRIzol Reagent (Thermo Fisher Scientiﬁc). After quantitation, RNA was reverse to cDNA using a PrimeScript RT reagent kit (Seyotin, China), and then, quantitative real-time PCR was performed by using SYBR Premix ExTaQTM II (Seyotin, China). The mRNA levels are normalized to GAPDH, and the primers used above are listed in Table 1.

2.10. Western Blotting Assay. The total proteins were extracted from cells or exosomes and quantiﬁed by the BCA assay kit (Seyotin, China). Proteins were separated on a 10% SDS-PAGE gel on ice and then transferred onto a PVDF membrane. After blocking with 5% bovine serum albumin (BSA), PVDF membranes were incubated with primary antibodies VEGF (Cat No.50661, CST), CD31 (Cat No.3528, CST), CD9 (Cat No.98327, CST), CD63 (Cat No.55081, CST), CD81 (Cat No.10037, CST), BMP2 (Cat No. 66383-1-Ig, Proteintech), Smad5 (Cat No. 67052-1-Ig, Proteintech), and phosphorylated Smad5 (Cat No.

![Figure 1: Conditioned medium (CM) extracted from SW480-resistant colon cancer cells enhance angiogenesis. HUVECs treated with CM of SW480/oxaliplatin and SW480 cells. (a) Proliferation assay of HUVECs. (b) The Transwell assay determined the HUVECs migration. (c) Photomicrographs of tube-like structures and quantification of the tube number. (d) The mRNA level of VEGF and CD31. (e) Then, protein expression of CD31 and VEGF in HUVECs. All above experiments were repeatedly performed 3 times; data are shown as the means ± SD. *P < 0.05, **P < 0.01.](image-url)
**Figure 2:** Characterization of exosomes of SW480/oxaliplatin cells. Exosomes were extracted from SW480/oxaliplatin and SW480 cells and then co-cultured with HUVECs. (a) Transmission electron photomicrograph of exosomes. (b) Protein expression of CD9, CD63, and CD81. (c) Confocal images of PKH67-labeled exosomes taken up by HUVECs. All the above experiments were repeatedly performed 3 times; data are shown as the means ± SD. *P < 0.05, **P < 0.01.

**Figure 3:** SW480/oxaliplatin cell-derived exosomes promotes cell proliferation. Exosomes were extracted from SW480/oxaliplatin and SW480 cells and then co-cultured with HUVECs. Effects of SW480/oxaliplatin cell-derived exosomes on proliferation of HUVECs were detected by EdU. All the above experiments were repeatedly performed 3 times; data are shown as the means ± SD. *P < 0.05, **P < 0.01.
Figure 4: Continued.
9516, CST) overnight at 4°C and then goat antirabbit IgG (Cat No. 60004-1-Ig, Proteintech) at room temperature for 1 h. Bands were visualized by ECL (Seyotin, China). All antibodies used above were purchased from Cell Signaling Technology and Proteintech.

2.11. Small Interfering RNA (siRNA) Transfection. BMP-2 or negative control siRNA sequences were synthesized by GenePharma (Hangzhou, China). HUVECs were transfected with siRNA using Lipofectamine 2000 (Cat No. 11668019, Thermo Fisher, Waltham, MA, USA) following the manufacturer’s instructions.

2.12. Statistical Analysis. Data were expressed as mean ± SD and analyzed for the significant difference using SPSS 22.0. The differences between two groups were analyzed by Student t test, and multiple groups were by one-way ANOVA. P less than 0.05 was considered statistically significant.

3. Results

3.1. Conditioned Medium (CM) Extracted from SW480-Resistant Colon Cancer Cells Enhance Angiogenesis. We explored the mechanisms of tumor angiogenesis by using SW480-resistant colon cancer. After culturing, the CM of both cells were collected and co-cultured with HUVECs. Compared with the CM of SW480 cells, the CM of SW480/oxaliplatin cells promoted cell activity of HUVECs (Figure 1(a)). Figures 1(b) and 1(c) find that the number of migration and tube formation of HUVECs in the SW480/oxaliplatin group was 1.64 and 1.28 times higher than that in the SW480 group. Additionally, the CM of SW480/oxaliplatin cells increased the mRNA levels and protein expression of VEGF and CD31 (markers of endothelial cell function) of HUVECs (Figures 1(d) and 1(e)). These findings suggested that the CM of SW480/oxaliplatin cells promoted the proliferation, migration, and tube formation of HUVECs.

Control  SW480-exos  SW480/Oxaliplatin-exos

VEGF
CD31
p-Smad5
Smad5
GAPDH

Relative protein expression of VEGF

Relative protein expression of CD31

$P = 0.03$

$P = 0.007$

$P = 0.04$

$P < 0.05$, $**P < 0.01$.

Figure 1: SW480/oxaliplatin cell-derived exosomes accelerates angiogenesis. Exosomes were extracted from SW480/oxaliplatin and SW480 cells and then co-cultured with HUVECs. (a) The Transwell assay determined the HUVECs migration. (b) Photomicrographs of tube-like structures and quantification of the tube number. (c) The protein expression of CD31, VEGF, and phosphorylation Smad5 in HUVECs. All the above experiments were repeatedly performed 3 times; data are shown as the means ± SD.

Control  SW480-exos  SW480/Oxaliplatin-exos

Relative protein expression of p-Smad5/Smad5

Relative protein expression of VEGF

Relative protein expression of CD31

$P < 0.05$, $**P < 0.01$.

Figure 4: SW480/oxaliplatin cell-derived exosomes accelerates angiogenesis. Exosomes were extracted from SW480/oxaliplatin and SW480 cells and then co-cultured with HUVECs. (a) The Transwell assay determined the HUVECs migration. (b) Photomicrographs of tube-like structures and quantification of the tube number. (c) The protein expression of CD31, VEGF, and phosphorylation Smad5 in HUVECs. All the above experiments were repeatedly performed 3 times; data are shown as the means ± SD. $*P < 0.05$, $**P < 0.01$. 
**Figure 5:** Continued.
3.2. Exosomes Extracted SW480/Oxaliplatin Cell Promote Angiogenesis. Based on the proven important role of exosomes in intracellular conduction, we next examined the effects of exosomes derived from the CM of SW480/oxaliplatin cell on promoting angiogenesis. After the exosomes were extracted, they were examined by TEM (Figure 2(a)). Moreover, the expression of CD9, CD63, and CD81 (exosomal positive markers) were significantly increased (Figure 2(b)). Then, the exosomes were labeled with PKH67 and co-cultured with HUVECs (Figure 2(c)).

The cell proliferation was evaluated by EdU incorporation and found that exosomes derived from the CM of SW480/oxaliplatin cell significantly enhanced proliferation of HUVECs (Figure 3). In addition, the HUVECs co-

![Figure 5: SW480/oxaliplatin exosomes are enriched in BMP-2, which improve angiogenesis via the inhibition of the Smad signaling pathway. HUVECs were co-cultured with SW480/oxaliplatin exosomes (40 μg/mL) with or without the treatment of si-RNA. (a) The expression of BMP-2 in exosomes. (b) Proliferation assay of HUVECs. (c) The Transwell assay determined the HUVECs migration. (d) The expression of CD31 detected by immunofluorescence. (e) The protein expression of VEGF and phosphorylation Smad5 in HUVECs. All above experiments were repeatedly performed 3 times; data are shown as the means ± SD. *P < 0.05, **P < 0.01.]
cultured with the exosomes of SW480/oxaliplatin cells had higher migration, as well as tube formation than that of HUVECs co-cultured with the exosomes of SW480 cells (Figures 4(a) and 4(b)). Furthermore, the mRNA and protein expression of VEGF and CD31 of HUVECs was increased in the SW480/oxaliplatin-exos group, compared

**Figure 6:** SW480/oxaliplatin exosomes promotes angiogenesis in vivo. BALB/c nude mice were injected with SW480 cells and SW480-exos or SW480/oxaliplatin-exos for 28 days \((n = 6)\). (a and b) The size and volume of the subcutaneous tumors in mice. (c) BMP-2 expression detected by immunohistochemical staining. (d) The protein expression of VEGF and CD31 in tumors. All above experiments were repeatedly performed 3 times; data are shown as the means ± SD. *\( P < 0.05 \), **\( P < 0.01 \).
with the SW480-exos group (Figures 4(c) and S1). Collectively, we found that SW480/oxaliplatin exosomes promoted angiogenesis of HUVECs.

3.3. BMP-2 Increased in SW480/Oxaliplatin Exosomes and Enhanced Angiogenesis via Inhibiting the Smad Signaling Pathway. Next, we investigated the potential mechanisms by which SW480/oxaliplatin exosomes promote angiogenesis. As displayed in Figure 4(c), compared with SW480 exosomes, SW480/oxaliplatin exosomes decrease the expression of phosphorylation Smad5 in HUVECs. Previous studies report that BMP-2 is a member of transforming growth factor-β/BMP superfamily, which exerts a variety of biological functions by regulating TGF-β/Smad signaling pathways [12]. The results of Western blotting showed that the expression of BMP-2 in SW480/oxaliplatin exosomes was 2.3-folds higher than that in SW480 exosomes (Figure 5(a)). To confirm the importance of BMP2 in SW480/oxaliplatin exosomes promoted angiogenesis, we performed siRNA-mediated knockdown in HUVECs. As shown in Figures 5(b) and 5(c) and S2, knockdown of BMP2 attenuates the increasing effect of SW480/oxaliplatin exosomes on cell proliferation, migration, and tube formation. Moreover, immunofluorescence and Western blotting indicated that silencing of BMP2 significantly reduced the expression of CD31, VEGF, and phosphorylation Smad5 induced by SW480/oxaliplatin exosomes (Figures 5(d) and 5(e)). Collectively, high levels of BMP-2 contained in SW480/oxaliplatin exosomes inhibited the Smad signaling pathway, thus promoting angiogenesis of HUVECs.

3.4. SW480/Oxaliplatin Exosomes Promote Angiogenesis In Vivo. Next, we investigated the proliferation and angiogenesis of SW480/oxaliplatin exosomes in mice. After the injection for 28 days, mice in the SW480/oxaliplatin group had a bigger size and tumor volumes than that in the SW480 group, and there was a significant difference between the two groups ($P < 0.05$, Figures 6(a) and 6(b)). Moreover, more BMP2-positive cells were observed in mice of the SW480/oxaliplatin group than SW480 group (Figure 6(c)). Then, we detected the angiogenesis of SW480/oxaliplatin exosomes in vivo by immunofluorescence staining of CD31. Compared with the SW480 group, more CD31-positive cells were found in the SW480/oxaliplatin group (Figure S3). The results of Western blotting showed the up-regulation of VEGF and CD31 protein expression in the SW480/oxaliplatin group (Figure 6(e)). These results indicated that SW480/oxaliplatin exosomes could enhance proliferation and angiogenesis in vivo, which could via the up-regulation of BMP2.

4. Discussion

Multidrug resistance refers to the simultaneous resistance of tumor cells to various drugs with different structures and chemotherapy mechanisms [4]. Mechanisms of drug resistance have been reported, including (1) activation of the drug target enzyme DNA topoisomerase N or detoxifying enzyme glutathione S-transferase [19]; (2) DNA self-repair [20]; and (3) apoptosis resistance of cancer cells and changes in some signaling pathways [21]. ATP-binding cassette (ABC) is one of the main causes of multidrug resistance of tumor cells, which can extract drugs from tumor cells to the outside of the cell through ATP-dependent membrane transporter to reduce the concentration of drugs in the cell [22]. However, how drug-resistant cancer cells regulate angiogenesis remains unclear. In this study, we found that exosomes derived from SW480/oxaliplatin cells promoted cell proliferation and migration and ultimately angiogenesis. The high levels of BMP-2 contained in SW480/oxaliplatin exosomes promote angiogenesis by inhibiting the Smad signaling pathway.

Previous studies considered exosomes to be merely “fragments” of exogenous cells. An increasing number of studies have found that exosomes play an increasingly important role in mediating cell-to-cell communication [23, 24]. It can be taken up by the recipient cells by carrying a variety of molecules including proteins, miRNA, DNA, and lipids and play a series of biological roles in the recipient cells [24]. Tumor cell-derived or tumor-associated exosomes are closely related to the formation of tumor drug resistance [25]. Adriamycin-resistant breast cancer cell line MCF-7/ADR can mediate the formation of drug resistance of sensitive cells MCF-7 through exosomes [26]. Cancer-associated fibroblasts (CAFs) secreted exosomes and promote metastasis and chemotherapy resistance of CRC [27]. The main mechanisms of exosomes mediating the formation of tumor drug resistance are as follows [28, 29]: (1) exosomes carrying drugs out of the body; (2) exosomes delivering drug-resistant proteins, which are one of the main mechanisms mediating the formation of tumor drug resistance; and (3) exosomes delivering noncoding RNAs (ncRNAs). In this study, we found that the proliferation, migration, and catheterization of HUVECs co-cultured with SW480/oxaliplatin exosomes were enhanced, suggesting that exosomes of drug-resistant cells could increase the angiogenesis of endothelial cells. It will be of great theoretical and practical significance to identify specific biomolecules that affect vascular production in exosomes of drug-resistant cells.

BMP2 mRNA expression has been found in breast cancer, and it has been shown that BMP2 promoted the proliferation of MCF-7 cells [30]. Hardwick et al. detected the expression of BMP-2 in colon tissue of 6 types of colon cancer and genetic adenomatous polyposis (FAP) patients and concluded that BMP-2 resulted in decreased apoptosis and cell adhesion in mature colon epithelial cells [31]. Sporadic early-onset colorectal cancer (EOCRC) has increased expression of BMP2, which is different from APC-mutated organs [32]. Smad4-deficient CRC cells induce high levels of BMP2 in fibroblasts, which enhance CRC invasiveness and metastasis [33]. Our study demonstrated that secretory BMP-2 acts as a tumor promoter by promoting angiogenesis in the tumor microenvironment. In addition, TGF-β inhibited BMP2 mRNA expression in primary embryonic rats or osteocyte cultures [34]. Consistent with this, we found TGFβ1 attenuated the enhanced angiogenesis caused by SW480/oxaliplatin exosomes in HUVECs.

Smad5 is a TGF-β superfamily protein that transmits signals from the cell membrane to the cell nucleus via the
TGF-β signaling pathway [35]. When Smad5 is degraded or deleted, normal signaling is disrupted, allowing cells to escape TGF-β-regulated growth inhibition and becomes cancerous [35]. The down-regulation of Smad5 inhibited the expression of N-cadherin, matrix metalloproteinase 9, Snail, and Vimentin while elevating E-cadherin expression, thus inhibiting EMT, cell proliferation, migration, and invasion in NPC [36]. Through the interaction between TGF/Smad pathway and Wnt pathway, the TGF/Smad pathway can jointly coordinate the occurrence of tumor epithelial to mesenchymal transition (EMT) [37]. After the occurrence of tumor EMT, the expression of N-mucin is increased. It weakens the adhesion between tumor cells, facilitates metastasis and infiltration, and promotes the movement and metastasis of tumor cells [38]. BMP-2 plays a different role in different stages of tumor progression by acting on the Smad signaling pathway. BMP-2 promotes epithelial-to-mesenchymal transition and breast cancer stemness via Rb and CD44-Smad4 signaling pathways [39]. The proliferation of ovarian cancer cell lines was enhanced by BMP2 and suppressed by dorsomorphin via Smad5 in vitro [38]. BMP/Smad5 signaling plays an important role and, therefore, becomes a potential therapeutic target in serous ovarian cancer.

5. Conclusion
In summary, our results suggested that BMP-2-rich exosomes inhibited the Smad signaling pathway, thereby promoting angiogenesis and cell drug resistance. Our findings would provide new insights into the potential of BMP-2 as a novel antiangiogenesis target in CRC.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
SY and LY have contributed to the study’s conception and design. XLW has contributed to the administrative support. HS and YSW have contributed to the provision of study materials or patients. CPS and HWH have contributed to the collection and assembly of data. CSW and YXX have contributed to the data analysis and interpretation. All authors have contributed to the writing of the manuscript and the final approval of manuscript.

Acknowledgments
This work was supported by the Natural Science Foundation of Anhui Province (2016QK056), the Natural Science Foundation of Anhui Traditional Chinese Medicine (2020cyb25), the Key Project of Education Department of Anhui Medical University (2019xj218), and the Key Project of Education Department of Lu’an Hospital of Anhui Province (2020kykt01). The funding helps us complete the data collection. This manuscript has been preprinted [DOI:10.21203/rs.3.rs-695878/v1] [40].

Supplementary Materials
Figure S1 SW480/oxaliplatin cell-derived exosomes promote angiogenesis. The mRNA expression of CD31 and VEGF. Data are shown as the means ± SD. *P < 0.05, **P < 0.01. Figure S2 SW480/oxaliplatin exosomes improve cell proliferation. The Transwell assay determined the HUVECs migration. Data are shown as the means ± SD. *P < 0.05, **P < 0.01. Figure S3 SW480/oxaliplatin exosomes promotes angiogenesis in vivo. The expression of CD31 detected by immunofluorescence. Data are shown as the means ± SD. *P < 0.05, **P < 0.01. (Supplementary Materials)

References
[1] H. Brody, “Colorectal cancer,” Nature, vol. 521, no. 7551, p. S1, 2015, PMID: 25970450.
[2] R. Dienstmann, R. Salazar, and J. Tabernero, “Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients,” Journal of Clinical Oncology, vol. 33, no. 16, pp. 1787–1796, 2015.
[3] T. Rivera Vargas and L. Apetoh, “Danger signals: chemotherapy enhancers?,” Immunological Reviews, vol. 280, no. 1, pp. 175–193, 2017, PMID: 29027217.
[4] M. Sun, X. Chen, and Z. Yang, “Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines,” Analytica Chimica Acta, vol. 1206, article 339761, 2022.
[5] H. Zhang, T. Deng, R. Liu et al., “Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis,” Nature Communications, vol. 8, no. 1, p. 15016, 2017.
[6] G. Housman, S. Byler, S. Heerboth et al., “Drug resistance in cancer: an overview,” Cancers (Basel), vol. 6, no. 3, pp. 1769–1792, 2014.
[7] M. Bredel and J. Zentner, “Brain-tumour drug resistance: the bare essentials,” The Lancet Oncology, vol. 3, no. 7, pp. 397–406, 2002, PMID: 31220978.
[8] K. Han, F. W. Wang, C. H. Cao et al., “CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17,” Molecular Cancer, vol. 19, no. 1, p. 60, 2020.
[9] J. Lu, Y. H. Wang, C. Yoon et al., “Circular RNA circRanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis,” Cancer Letters, vol. 28, no. 471, pp. 38–48, 2020.
[10] X. Xie, J. Yao, Y. Wang, and B. Ni, “Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis,” Drug Delivery, vol. 29, no. 1, pp. 1257–1271, 2022.
[11] D. D. Yu, Y. Wu, H. Y. Shen et al., “Exosomes in development, metastasis and drug resistance of breast cancer,” Cancer Sci, vol. 106, no. 8, pp. 959–964, 2015.
[12] Y. Xu, A. Qiu, F. Peng, X. Tan, J. Wang, and X. Gong, “Exosomal transfer of circular RNA FBXW7 ameliorates the
Chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p,” *Neoplasma*, vol. 68, pp. 108–118, 2021.

[13] H. Tian, J. Zhao, E. J. Brochmann, J. C. Wang, and S. S. Murray, “Bone morphogenetic protein-2 and tumor growth: diverse effects and possibilities for therapy,” *Cytokine & Growth Factor Reviews*, vol. 34, pp. 73–91, 2017.

[14] Z. Hong, C. Shixia, and F. Qiang, “Exosomes from CD133 cells carrying circ-ABC1 mediate cell stemness and metastasis in colorectal cancer,” *Journal of Cellular Biochemistry*, vol. 121, pp. 3286–3297, 2020.

[15] J. Zhang, Y. Ge, L. Sun et al., “Effect of bone morphogenetic protein-2 on proliferation and apoptosis of gastric cancer cells,” *Int J Med Sci*, vol. 9, no. 2, pp. 184–192, 2012.

[16] E. M. Langenfeld, Y. Kong, and J. Langenfeld, “Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin,” *Molecular Cancer Research*, vol. 3, no. 12, pp. 679–684, 2005, PMID: 16380505.

[17] P. C. Feng, X. F. Ke, H. L. Kuan, L. L. Pan, Q. Ye, and J. B. Wu, “BMP2 secretion from hepatocellular carcinoma cell HepG2 enhances angiogenesis and tumor growth in endothelial cells via activation of the MAPK/p38 signaling pathway,” *Stem Cell Research & Therapy*, vol. 10, no. 1, p. 237, 2019.

[18] G. Szakás, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” *Nature Reviews. Drug Discovery*, vol. 5, no. 3, pp. 219–234, 2006, PMID: 16518375.

[19] K. Bukowski, M. Kciuk, and R. Kontek, “Mechanisms of multidrug resistance in cancer chemotherapy,” *International Journal of Molecular Sciences*, vol. 21, no. 9, p. 3233, 2020.

[20] Y. G. Assaraf, A. Brozovic, A. C. Gonçalves et al., “The multifactorial nature of clinical multidrug resistance in cancer,” *Drug Resistance Updates*, vol. 46, article 100645, 2019.

[21] I. S. Mohammad, W. He, and L. Yin, “Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR,” *Biomedicine & Pharmacotherapy*, vol. 100, pp. 335–348, 2018.

[22] R. Kalluri and V. S. LeBlu, “The biology, function, and biomedical applications of exosomes,” *Science*, vol. 367, no. 6478, 2020.

[23] E. V. Batrakova and M. S. Kim, “Using exosomes, naturally-equipped nanocarriers, for drug delivery,” *J Control Release*, vol. 10, no. 219, pp. 396–405, 2015.

[24] L. Zhang and D. Yu, “Exosomes in cancer development, metastasis, and immunity,” *Biochim Biophys Acta Rev Cancer*, vol. 1871, no. 2, pp. 455–468, 2019.

[25] X. Wang, C. Xu, Y. Hua et al., “Exosomes play an important role in the process of psoralen reverse multidrug resistance of breast cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 35, no. 1, p. 186, 2016.

[26] J. L. Hu, W. Wang, X. L. Lan et al., “CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer,” *Molecular Cancer*, vol. 18, no. 1, p. 91, 2019.

[27] L. Mashouri, H. Yousef, A. R. Aref, A. M. Ahadi, F. Molaei, and S. K. Alahari, “Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance,” *Molecular Cancer*, vol. 18, no. 1, p. 75, 2019.

[28] N. Milman, L. Ginini, and Z. Gil, “Exosomes and their role in tumorigenesis and anticancer drug resistance,” *Drug Resistance Updates*, vol. 45, pp. 1–12, 2019.

[29] M. Raida, J. H. Clement, R. D. Leek et al., “Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis,” *Journal of Cancer Research and Clinical Oncology*, vol. 131, pp. 741–750, 2005.

[30] J. C. Hardwick, G. R. Van Den Brink, S. A. Bleuming et al., “Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon,” *Gastroenterology*, vol. 126, no. 1, pp. 111–121, 2004, PMID: 14699493.

[31] H. H. N. Yan, H. C. Siu, S. L. Ho et al., “Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles,” *Gut*, vol. 69, pp. 2165–2179, 2020.

[32] P. K. Panda, P. P. Naik, P. P. Prabharaj et al., “Abrus agglutinin stimulates BMP-2-dependent differentiation through autophagic degradation of β-catenin in colon cancer stem cells,” *Molecular Carcinogenesis*, vol. 57, no. 5, pp. 664–677, 2018.

[33] T. Katagiri, A. Yamaguchi, M. Komaki et al., “Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage,” *The Journal of Cell Biology*, vol. 127, no. 6, pp. 1755–1766, 1994.

[34] J. Orlowski, “SMAD5 signaling: more than meets the nuclei,” *Cell Res.*, vol. 27, no. 9, pp. 1075–1076, 2017.

[35] Y. J. Zheng, J. Y. Zhao, T. S. Liang et al., “Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma,” *FASEB J.*, vol. 33, no. 11, pp. 12915–12928, 2019.

[36] Y. Zeng, J. Zhu, D. Shen et al., “Corrigendum Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial-mesenchymal transition in A549 cell lines,” *Erratum in: Int J Oncol.*, vol. 58, no. 2, pp. 276–277, 2021.

[37] H. L. Li, Q. Y. Li, M. J. Jin et al., “A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression,” *Journal of Cancer Research and Clinical Oncology*, vol. 147, no. 6, pp. 1569–1585, 2021.

[38] P. Huang, A. Chen, W. He et al., “BMP-2 induces EMT and breast cancer stemness through Rb and CD44,” *Cell Death Discov.*, vol. 3, no. 1, p. 17039, 2017.

[39] J. Peng, Y. Yoshioka, M. Manda et al., “The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer—a potential therapeutic target,” *Molecular Carcinogenesis*, vol. 55, no. 4, pp. 335–345, 2016.

[40] S. Yang, L. Yao, X. Wang et al., “Exosomes derived from SW480-resistant colon cancer cells are promote angiogenesis via BMP-2/Smad5 signaling pathway,” 2021.